Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS - Scorecard - MDSpire
Advertisement
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
Clinical Scorecard: Impact of Previous Treatments on the Efficacy of Imetelstat in Patients with Transfusion-Dependent, ESA-Relapsed or -Refractory/-Ineligible Lower-Risk Myelodysplastic Syndromes
At a Glance
Category
Detail
Condition
Lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia
Key Mechanisms
Ineffective hematopoiesis and abnormal blood cell development leading to anemia and RBC transfusion dependence; imetelstat acts as a direct and competitive telomerase inhibitor
Target Population
Patients with LR-MDS who are transfusion-dependent and relapsed, refractory, or ineligible for erythropoiesis-stimulating agents (ESAs)
Care Setting
Hematology/oncology outpatient or specialized care centers managing LR-MDS
Key Highlights
Imetelstat demonstrated clinically meaningful and durable efficacy with a median duration of ≥8-week RBC transfusion independence of 55 weeks in pooled LR-MDS patients.
Efficacy of imetelstat was observed in patients previously treated with ESAs, luspatercept, and lenalidomide but showed limited activity after prior hypomethylating agents (HMAs).
Patients ineligible for ESA therapy (serum erythropoietin >500 mU/mL) achieved notable RBC transfusion independence rates, especially those treatment-naive to prior therapies.
Guideline-Based Recommendations
Diagnosis
Identify LR-MDS patients with transfusion-dependent anemia and assess prior treatment history including ESA exposure and serum erythropoietin levels.
Management
Consider imetelstat for LR-MDS patients with RBC transfusion dependence who are relapsed, refractory, or ineligible for ESAs.
Administer imetelstat intravenously every 4 weeks at 7.1 mg/kg over 2 hours.
Avoid concurrent anticancer, ESA, or erythropoiesis maturation agent therapies during imetelstat treatment.
Monitoring & Follow-up
Monitor RBC transfusion independence duration and hemoglobin levels to assess treatment response.
Evaluate for hematologic improvement and potential adverse effects during therapy.
Risks
Limited efficacy of imetelstat observed in patients with prior hypomethylating agent therapy.
Potential safety considerations as per clinical trial data; no QTc prolongation observed.
Patient & Prescribing Data
LR-MDS patients with RBC transfusion dependence, including those with prior ESA, luspatercept, lenalidomide, or HMA therapies, and ESA-ineligible patients.
Imetelstat shows durable RBC transfusion independence across multiple prior treatment subgroups, with highest efficacy in ESA-naive and ESA-ineligible patients; limited activity after prior HMA exposure.
Clinical Best Practices
Assess prior treatment exposures comprehensively to inform imetelstat use and anticipate response.
Consider imetelstat as a treatment option for LR-MDS patients who have failed or are ineligible for ESAs.
Regularly monitor transfusion requirements and hemoglobin to evaluate treatment efficacy.
Avoid concurrent use of other erythropoiesis-stimulating or anticancer agents during imetelstat therapy.
by Rami S. Komrokji, Valeria Santini, Amer M. Zeidan, Mikkael A. Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, Yazan F. Madanat, María Díez-Campelo, David Valcárcel, Anna Jonášová, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Faye Feller, Michael R. Savona, Uwe Platzbecker
